Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Iron Overload and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DMT1/SLC11A2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC11A2 Extracellular Loop Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View SLC11A2 Products |
| Gene Delivery | SLC11A2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and metal flux assays. |
View SLC11A2 Products |
| Benchmark Ab | Anti-SLC11A2 Recombinant Antibody Recombinant positive control for flow cytometry and IHC. |
View SLC11A2 Products |
| Validator | SLC11A2 siRNA Set For target knockdown verification in functional assays. |
View SLC11A2 Products |
| Related Target A | SLC40A1 (Ferroportin) The sole cellular iron exporter; synergistic target for systemic iron regulation. |
View SLC40A1 Products |
| Related Target B | TFRC (Transferrin Receptor/CD71) Primary receptor for transferrin-bound iron uptake; co-expressed in high-iron demand tumors. |
View TFRC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining 12-TMD Conformation | Lentivirus Premade Particles for stable cell line generation, enabling native-state functional assays. |
| Subfamily Off-Target Screening | Homolog panel screening reagents (SLC11A1/Mramp1) strictly verified by mass spectrometry. |
| Lack of Controls | Clinical-grade Benchmark Antibodies and validated positive control cell lines. |
| False Positives in Small Molecule Screens | Sequence-verified siRNA sets included for target-specific knockdown validation. |
Live DMT1/SLC11A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DMT1/SLC11A2 therapeutics is intensifying, with major players shifting focus from traditional chelators to targeted small-molecule inhibitors and monoclonal antibodies. As first-generation therapies for iron overload and colorectal cancer reach the clinic, the next wave of R&D is targeting the intracellular transport machinery to bypass systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Iron Overload, Beta-Thalassemia | Metal Flux Assays (Need SLC11A2 Lentivirus for stable cell lines) |
| Monoclonal Antibodies | Biopharma Innovators | Colorectal Cancer, Solid Tumors | Surface Conformation Binding (Need high-purity extracellular loop proteins) |
| RNA Therapeutics | Gene Therapy Biotechs | Hematological Disorders | In vitro Knockdown Validation (Need sequence-verified siRNA sets) |